Pyridorin in Diabetic Nephropathy (PIONEER)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin (Pyridoxamine Dihydrochloride) in Subjects With Nephropathy Due to Type 2 Diabetes (PIONEER)
Sponsor: Collaborative Study Group (CSG)
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Collaborative Study Group (CSG)
More terminations from Collaborative Study Group (CSG)
Listed as NCT02156843, this PHASE3 trial focuses on Diabetic Kidney Disease and Diabetic Nephropathy and remains terminated or withdrawn. Sponsored by Collaborative Study Group (CSG), it has been updated 7 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Collaborative Study Group (CSG)
- Medpace, Inc.
- NephroGenex, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Arvada, United States , Aschaffenburg, Germany , Asheville, United States , Ashkelon, Israel , Aurora, United States , Balatonfüred, Hungary , Barcelona, Spain , Beersheba, Israel , Berlin, Germany and 108 more locations